Bookmark
Forward
QuickView for Nabumetone (compound)
PubChem
| Name: | nabumetone |
|---|---|
| PubChem Compound ID: | 4409 |
| Molecular formula: | C15H16O2 |
| Molecular weight: | 228.286 g/mol |
| Synonyms: |
Mebutan; Relifen; Spectrum2_001969; KBio2_001966; NCGC00016853-01; Spectrum_001486; Nabumetonum [INN-Latin]; KBioSS_001966; KBio2_004534; 2-Butanone, 4-(6-methoxy-2-naphthalenyl)-.
show more » |
DrugBank
Identification
| Name: | nabumetone |
|---|---|
| Name (isomeric): | DB00461 |
| Drug Type: | small molecule |
| Synonyms: |
Nabumetona; Nabumetonum [INN-Latin]
|
| Brand: | Balmox, Listran, Relifen, Flambate, Consolan, Relifex, Unimetone, Dolsinal, Prodac, Nabuser, Arthaxan, Mebutan, Relafen, Relif |
| Category: | Antineoplastic Agents |
| CAS number: | 42924-53-8 |
Pharmacology
| Indication: | For acute and chronic treatment of signs and symptoms of osteoarthritis and rheumatoid arthritis. |
|---|---|
| Pharmacology: |
Nabumetone is a naphthylalkanone. Is is a non-selective prostaglandin G/H synthase (a.k.a. cyclooxygenase or COX) inhibitor that acts on both prostaglandin G/H synthase 1 and 2 (COX-1 and -2). Prostaglandin G/H synthase catalyzes the conversion of arachidonic acid to prostaglandin G2 and prostaglandin G2 to prostaglandin H2. Prostaglandin H2 is the...
show more » |
| Mechanism of Action: | The parent compound is a prodrug, which undergoes hepatic biotransformation to the active component, 6-methoxy-2-naphthylacetic acid (6MNA), that is a potent inhibitor of prostaglandin synthesis, most likely through binding to the COX-2 and COX-1 receptors. |
| Absorption: | Well absorbed from the gastrointestinal tract. Coadministration of food increases the rate of absorption and subsequent appearance of 6MNA (the active metabolite) in the plasma but does not affect the extent of conversion of nabumetone into 6MNA. |
| Protein binding: | The active metabolite, 6MNA, is more than 99% bound to plasma proteins. |
| Biotransformation: | Undergoes rapid biotransformation to the principal active metabolite, 6-methoxy-2-naphthylacetic acid (6MNA). Approximately 35% of a 1000 mg oral dose of nabumetone is converted to 6MNA and 50% is converted into unidentified metabolites which are subsequently excreted in the urine. |
| Route of elimination: | Approximately 35% of a 1000 mg oral dose of nabumetone is converted to 6MNA and 50% is converted into unidentified metabolites which are subsequently excreted in the urine. |
| Half Life: | Approximately 23 hours for the active metabolite, 6MNA. Increased in patients with renal insufficiency. |
| Clearance: | 20 - 30 mL/min |
| Toxicity: | The one overdose occurred in a 17-year-old female patient who had a history of abdominal pain and was hospitalized for increased abdominal pain following ingestion of 30 nabumetone tablets (15 grams total). Stools were negative for occult blood and there was no fall in serum hemoglobin concentration. The patient had no other symptoms. |
| Affected organisms: | Humans and other mammals |
Interactions
| Food interaction: |
| ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Drug interaction: |
|
Targets
